Issue 5/2003
Content (15 Articles)
Nonpharmacologic Treatment of Hypertension in Primary Health Care
Norman M. Kaplan, Donald G. Vidt
A Comparison of Outcomes with Angiotensin-converting Enzyme
Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
Gozewÿn Laverman, Piero Ruggenenti, Giuseppe Remuzzi
Regression of left ventricular hypertrophy: Are there preferred drugs?
Joseph A. Diamond, Robert A. Phillips
Isolated systolic hypertension and the risk of vascular disease
Tim Nawrot, Elly Den Hond, Lutgarde Thijs, Jan A. Staessen
Impact of the obesity epidemic on hypertension and renal disease
John E. Hall, Daniel W. Jones, Jay J. Kuo, Alexandre da Silva, Lakshmi S. Tallam, Jiankang Liu
Cardiometabolic syndrome: Pathophysiology and treatment
Jonathan P. Castro, Fadi A. El-Atat, Samy I. McFarlane, Ashish Aneja, James R. Sowers
Chronic kidney disease: Blood pressure, treatment goals, and cardiovascular outcomes
Matthew R. Weir
RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease
Jay Lakkis, Wei X. Lu, Matthew R. Weir
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
Marc S. Weinberg, Nicholas Kaperonis, George L. Bakris
How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?
Julian Segura, Helle Christiansen, Carlos Campo, Luis M. Ruilope
Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?
Douglas A. Nigbor, Julia B. Lewis